Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2010-07-21
2011-12-27
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
08084441
ABSTRACT:
Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.
REFERENCES:
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4886786 (1989-12-01), Lindstrom et al.
patent: 4943630 (1990-07-01), Jacquinet et al.
patent: 4987222 (1991-01-01), De Ambrosi et al.
patent: 5008253 (1991-04-01), Casu et al.
patent: 5037810 (1991-08-01), Saliba, Jr.
patent: 5158940 (1992-10-01), LaRocca et al.
patent: 5541166 (1996-07-01), Parish et al.
patent: 5605891 (1997-02-01), Prino et al.
patent: 6083933 (2000-07-01), Hahn
patent: 6143730 (2000-11-01), Parish et al.
patent: 6417173 (2002-07-01), Roufa et al.
patent: 6492349 (2002-12-01), Henderson
patent: 6537977 (2003-03-01), Kyogashima et al.
patent: 6689748 (2004-02-01), Theoharides
patent: 6979679 (2005-12-01), Marcum
patent: 7485629 (2009-02-01), Marcum
patent: 7504387 (2009-03-01), Marcum
patent: 7772210 (2010-08-01), Riehl et al.
patent: 2003/0232100 (2003-12-01), Theoharides
patent: 2004/0161476 (2004-08-01), Hahn et al.
patent: 2009/0137525 (2009-05-01), Marcum
patent: 1187798 (1985-05-01), None
patent: 1240929 (1988-08-01), None
patent: 2071898 (1991-04-01), None
patent: 2020199 (1991-12-01), None
patent: 2046037 (1992-01-01), None
patent: 2060223 (1992-08-01), None
patent: 2066785 (1992-11-01), None
patent: 2076063 (1993-02-01), None
patent: 2100657 (1993-05-01), None
patent: 2128160 (1995-01-01), None
patent: 2130295 (1995-02-01), None
patent: 2190107 (1995-11-01), None
patent: 2203621 (1998-04-01), None
patent: 2217134 (1998-04-01), None
patent: 2120367 (2004-05-01), None
patent: 0 636 631 (1995-02-01), None
patent: WO 93/09766 (1993-05-01), None
patent: WO 93/21193 (1993-10-01), None
patent: WO 9400135 (1994-01-01), None
patent: WO 02/09728 (2002-02-01), None
patent: WO 2004/034980 (2004-04-01), None
patent: WO 2004/073584 (2004-09-01), None
#Conte et al., Metabolic Fate of Exogenous Chondroitin Sulfate in Man Arzneim-Forsch./Drug Res. 41(11) 7, 1991, pp. 768-772.
#Hurst et al., A Deficit of Chondroitin Sulfate Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis, Urology, 1996, pp. 817-821, vol. 48.
#Hurst et al., A Deficit of Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis, European Urology Supplements, Official Journal of the European Association of Urology, 2002, pp. 10-13, vol. 2.
#Hurst et al., Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Lining, J. Urol., 1987, pp. 433-437, vol. 138.
#Kurth et al., The Interstitial Cystitis Syndrome: Intravesical and Oral Treatment, European Urology Supplements. 2002, pp. 2-9, vol. 2.
#Mast cells may account for success of GAG layer treatments, by editor Norman Bauman, [online][retrieved Jan. 15, 1999]www.ichelp.com.
#Medical Device License Homologation d'un Instrument medical.
#Parsons et al., The Role of Urinary Potassium in the Pathogenesis and Diagnosis of Interstitial Cystitis, J. Urol., 1998, pp. 1862-1867, vol. 159.
#Sant & Larock, Standard Intravesical Therapies for Interstitial Cystitis. In Urologic Clinics of North America, Feb. 1994, pp. 73-83, vol. 21, No. 1.
#Schick, Interstitial Cystitis: Diagnosis and Treatment, Journal of CME, Aug. 1998, pp. 55-66.
#Sorensen. Chondroitin Sulphate in the Treatment of Interstitial Cystitis and Chronic Inflammatory Disease of the Urinary Bladder, European Urology Supplements, 2002. pp. 14-16, vol. 2.
#Steinhoff et al., The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis, The Canadian Journal of Urology, Feb. 2002, pp. 1454-1458, vol. 9, No. 1.
#Steinhoff, The Efficacy of Chrondroitin Sulphate in Treating Interstitial Cystitis, European Urology Supplements, 2002. pp. 14-16. vol. 2.
PCT International Search Report, PCT/CA2004/000244, dated Dec. 13, 2004.
Hahn Sungtack Samuel
Riehl Peter R.
Peselev Elli
Stellar Pharmaceuticals, Inc.
TraskBritt P.C.
LandOfFree
Cystitis treatment with high dose chondroitin sulfate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cystitis treatment with high dose chondroitin sulfate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cystitis treatment with high dose chondroitin sulfate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305368